This trial is evaluating whether STP707 will improve 2 primary outcomes in patients with Tumors, Solid. Measurement will happen over the course of 28 Day Cycle.
This trial requires 40 total participants across 5 different treatment groups
This trial involves 5 different treatments. STP707 is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Tumors, solid do share common and similar causes with tumors, liquid. Genetic predisposition contributes to solid tumors. Both solid and liquid cancers can develop spontaneously.
The most common treatment for tumors (solitary or multiple) consists of surgery, and radiotherapy is also commonly used. The use of chemotherapy and immunotherapy are gaining acceptance. No consensus exists among medical experts about which treatment is most effective or most common for certain types of tumors.\n
The number of tumors, solid, increased substantially from 2000 to 2007, with an annual increase of more than 17%. Increases seen in these major tumor subtypes, malignant neoplasms, malignant tumors, and primary solid tumors, may have important implications for clinical practice (see image to right), prevention, and management for patients with tumors, particularly in the light of the growing number of people with cancer who are treated empirically (see image in top left panel to right).
A 2004 study(http://www.nejm.org/content/abstract/24/8/3328.full) found no clear evidence that a small percentage of tumors, solid do get cured. A majority of patients with advanced solid tumors do not survive for two years or more; however, a smaller proportion of patients do survive for longer than two years.
Tumors, solid is a cancer that forms in the body and tends to grow fast. Breast cancer, head and neck cancer, and lung cancer are the most common types of tumors that start in the breast, tongue and head and neck region, respectively. All these cancers are diagnosed in both males and females. Symptoms may include itching, soreness, discharge, or pain if the cancer has metastasized. Treatment typically includes surgery or radiation to destroy the cancer. More commonly, chemotherapy or targeted therapy are prescribed. Older people with tumors, solid are at higher risk of developing the syndrome of aging.
Tumors, solid, frequently present with weight loss and loss of appetite. A painless, firm mass that seems to be in the same location in each of the four limbs is the most specific sign for cancer, and may also lead to an underlying tumor. Other complaints may include skin pain, itching, or discoloration. A family history of cancer and a nonsteroidal inflammatory drug habit may help to identify tumors, solid.
These data support a model in which stp707 is involved in regulation of the trafficking of exosomes and/or sphingolipids, or proteins within the exosome. This may lead to an increase in the production of neurotoxic isoforms of the protease.
(i) [CT scan--]\n(1) is a common and noninvasive technique for determining whether tumors are growing and where they are growing.\n(2) can also determine whether tumors are growing in certain places, which can help doctors decide which part of the body should be treated surgically.\n(3) In recent years (2006), researchers have come up with ideas that can help surgeons to remove tumors more easily without damaging more normal healthy tissue, thus speeding up recovery and recovery time. (iii) [MRSI]\n\n(1) is a common and noninvasive technique for determining whether a tumor is growing and where it's growing.
One of the common side effects of Stp707 in clinical trials was [pain-related and/or non-pain related symptoms] but pain is still an important issue for stp707-treated patients. There is no known side effect that stops medication or prevents a new prescription. In addition, studies show that after stopping medication, symptoms disappear; for example, stopping Stp707 would remove the pain. The [common non-pain symptoms like loss of appetite, diarrhea, low temperature, coughing and/or a low white blood cell count]] could relate to the patient being older than 24 years old. Symptoms did not happen more often during or after the treatment. There is no known risk associated with long term use of stp707.
The long-term safety of Stp707, administered as a once-daily subcutaneous injection in conjunction with bortezomib, is consistent with those reported in phase I clinical trials and supports its further clinical development.
Stp707 is effective in patients with solid tumors where standard chemotherapy has received poor response (n = 7). Stp707 could decrease the risk of tumor invasion after surgery by increasing the cell’s expression of beta-catenin protein, by inhibiting beta-catenin and its effectors. Stp707 may be considered in addition to surgery for patients with solid tumors and it needs additional study.